Insulin Glargine Injection, Solution
Product Images NDC 72572-424

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Insulin Glargine (NDC 72572-424). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civica, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Site Of Injection On Body (Image 01)

An anatomical illustration showing common injection sites for subcutaneous administration of insulin glargine. Highlighted areas include the upper arms, abdomen, and front and sides of the thighs, indicating recommended locations for injection.*

FDA Label Image

Image-02 (Image 02)

An instructional exploded view diagram of an Insulin Glargine injection pen by Civica, Inc., labeled with parts including pen cap, cartridge holder, rubber seal, cartridge, pen body showing the drug label with expiration date, dose window, dose selector, injection button, and dose pointer. Below is a depiction of the pen needle assembly components: outer cap, inner cap, needle, and protective seal, noting the needle is not included.*

FDA Label Image

Image-03 (Image 03)

The image shows a single-dose pen device labeled INSULIN GLARGINE 100 units/mL solution for subcutaneous injection. The label includes the generic name insulin glargine-yfgn and the labeler, Civica, Inc. The NDC number 72572-424 is partially visible. The injection device has a teal-colored body and a white and purple dial for dose adjustment.*

FDA Label Image

Image-04 (Image 04)

Insulin Glargine 100 units/mL injection solution in a subcutaneous pen device. The image displays a portion of the blue pen injector with a close-up on the white label, showing space for lot and expiration dates. Manufactured by Civica, Inc. NDC 72572-424.*

FDA Label Image

Image-04a (Image 04a)

An instructional illustration showing the removal of a blue protective cap from a syringe needle. A hand is gripping the blue cap on the left, with the needle and syringe positioned to the right, partially visible with measurement markings. The illustration includes a pink arrow pointing left, indicating the direction to remove the cap.*

FDA Label Image

Image-05 (Image 05)

INSULIN GLARGINE-yfgn 100 units/mL injection solution in a prefilled syringe. The syringe is transparent with black dose markings and an orange protective cap. The label displays the product name Insulin Glargine-yfgn alongside the instruction 'For Single Patient Use Only.' The product is labeled by Civica, Inc.*

FDA Label Image

Image-06 (Image 06)

An instructional illustration showing a close-up of a vial with measurement markings, and a hand peeling back a protective seal from the vial's rubber stopper.*

FDA Label Image

Image-07 (Image 07)

An instructional illustration showing a person peeling off a protective seal from the top of an injection pen or vial cap. The image highlights the removal step with an upward arrow and displays hands holding the device to reveal the opening underneath the seal.*

FDA Label Image

Image-08 (Image 08)

An instructional diagram illustrating the steps to properly mix insulin glargine injection solution using two hands. The image shows one hand holding the vial and rotating it gently while the other hand holds the syringe and plunger, demonstrating a sequence of circular mixing motions before administration.*

FDA Label Image

Image-09 (Image 09)

An instructional illustration showing the removal of the outer cap from an insulin injection pen. A hand is lifting the cap upwards, with an arrow indicating the direction, and text advises to 'Keep outer cap.' The image focuses on proper handling of the pen's outer cap.*

FDA Label Image

Image-10 (Image 10)

Instructional illustration showing how to remove the inner cap from an insulin injection pen or syringe before use. The image depicts fingers pulling the cap upward, with an arrow indicating the direction to throw away the inner cap.*

FDA Label Image

Image-11 (Image 11)

An instructional illustration showing part of an insulin pen device with a close-up of the dose dial indicating units to be injected. The image includes a hand adjusting the dose selector on the blue pen, focusing on the numbers visible on the dial.*

FDA Label Image

Image-12 (Image 12)

An instructional illustration showing a hand holding a vial below a syringe. An arrow points upward toward the syringe, which is fitted with a needle cap featuring a drop of fluid. This appears to demonstrate the process of drawing medication from the vial into the syringe, likely related to subcutaneous injection preparation.*

FDA Label Image

Image-14 (Image 14)

An instructional illustration showing hands holding an Insulin Glargine-yfgn 100 units/mL injection pen. The image demonstrates preparing the pen for subcutaneous injection, including setting the dose by turning the dial on the pen.*

FDA Label Image

Image-15 (Image 15)

An instructional close-up image showing a dosage selection dial set to 48 units. The image illustrates the dosage selector mechanism commonly found on injection pens used for subcutaneous delivery of insulin glargine.*

FDA Label Image

Image-16 (Image 16)

An illustration showing a close-up view of an insulin pen dial displaying a dosage selection, with the marker pointing near the 50-unit mark. The graphic highlights an example dose of 49 units selected, used for demonstrating dose setting in an injection pen.*

FDA Label Image

Image-17 (Image 17)

An instructional illustration showing a hand holding a syringe with a vial attached, demonstrating the subcutaneous injection technique into the arm. The image includes a directional arrow indicating proper injection direction.*

FDA Label Image

Image-18 (Image 18)

An instructional illustration showing a hand holding a syringe with a vial, demonstrating the correct method to rotate or mix the vial by rolling it between the thumb and fingers. The image includes close-up circles highlighting the thumb and fingers' positions on the vial cap and body.*

FDA Label Image

Image-19 (Image 19)

An instructional illustration showing a hand holding a vial labeled with dosage markings, positioned horizontally. Next to it is a clock face with a 10-second segment highlighted, indicating a timing instruction related to the vial usage.*

FDA Label Image

Image-20 (Image 20)

An instructional illustration showing a hand removing a protective cap from a pen injector needle before use. The image emphasizes proper preparation of an injectable medication device, likely for subcutaneous administration.*

FDA Label Image

Image-21 (Image 21)

An instructional illustration showing a hand gripping the cap of a vial labeled '17'. The image uses arrows indicating a two-step process: first, twisting the cap counterclockwise, and second, lifting the cap upward to remove it from the vial.*

FDA Label Image

Image-22 (Image 22)

An instructional illustration showing hands handling a syringe with a needle cap being removed and a sharps disposal container visible nearby. The image likely demonstrates safe preparation or disposal steps related to injection use.*

FDA Label Image

Image-23 (Image 23)

Instructional illustration showing a hand holding a blue needle cap with an arrow pointing towards a syringe with a clear solution, indicating the step to remove the needle cover before injection.*

FDA Label Image

Image-24 (Image 24)

A line graph comparing glucose infusion rates over time after subcutaneous injection of insulin glargine and NPH insulin. The x-axis represents time in hours up to 30 hours, and the y-axis shows glucose infusion rate in mg/kg/min. Two lines represent insulin glargine (solid) and NPH insulin (dashed), with a marker indicating the end of the observation period.*

FDA Label Image

Image-26 (Image 26)

Packaging label for Insulin Glargine-yfgn Injection, 100 units/mL (U-100) by Civica, Inc. The label indicates it is for subcutaneous use, prescription only, and for single patient use only. The carton contains five 3 mL prefilled pens and includes manufacturer and use instructions.*

FDA Label Image

Image-27 (Image 27)

FDA Label Image

Image-28 (Image 28)

Insulin Glargine-yfgn 100 units/mL injection solution in a prefilled syringe labeled for single patient use. The syringe is marked with dosage graduations and includes a needle attached at one end. The label displays the product name, strength, and single-use indication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.